HCWB Insider Trading
Insider Ownership Percentage: 42.70%
Insider Buying (Last 12 Months): $305,032.00
Insider Selling (Last 12 Months): $0.00
HCW Biologics Share Price & Price History
Current Price: $2.04
Price Change: ▼ Price Decrease of -0.02 (-0.97%)
As of 12/4/2025 05:00 PM ET
HCW Biologics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/8/2025 | Gary M Winer | Director | Buy | 2,308 | $26.00 | $60,008.00 | 2,733 |  |
| 5/8/2025 | Lee Flowers | SVP | Buy | 962 | $26.00 | $25,012.00 | 5,720 | |
| 5/8/2025 | Rebecca Byam | CFO | Buy | 8,462 | $26.00 | $220,012.00 | 43,010 | |
| 9/14/2023 | Hing C Wong | CEO | Buy | 45 | $83.20 | $3,744.00 | 382,871 | |
| 9/13/2023 | Gary M Winer | Director | Buy | 13 | $82.00 | $1,066.00 | 398 | |
| 9/13/2023 | Rebecca Byam | CFO | Buy | 125 | $84.00 | $10,500.00 | 14,348 | |
| 9/11/2023 | Gary M Winer | Director | Buy | 2 | $82.00 | $164.00 | 372 | |
| 9/11/2023 | Rebecca Byam | CFO | Buy | 125 | $82.00 | $10,250.00 | 14,098 | |
| 9/8/2023 | Rebecca Byam | CFO | Buy | 125 | $80.80 | $10,100.00 | 13,973 | |
| 9/7/2023 | Gary M Winer | Director | Buy | 1 | $78.00 | $78.00 | 370 | |
| 9/6/2023 | Rebecca Byam | CFO | Buy | 125 | $78.00 | $9,750.00 | 13,723 | |
| 9/5/2023 | Gary M Winer | Director | Buy | 10 | $70.00 | $700.00 | 368 | |
| 6/9/2023 | Rebecca Byam | CFO | Buy | 500 | $82.40 | $41,200.00 | 13,598 | |
| 6/8/2023 | Lee Flowers | SVP | Buy | 250 | $86.40 | $21,600.00 | 2,782 | |
| 6/7/2023 | Rebecca Byam | CFO | Buy | 500 | $81.20 | $40,600.00 | 12,981 | |
| 6/5/2023 | Rebecca Byam | CFO | Buy | 500 | $66.80 | $33,400.00 | 12,004 | |
| 6/1/2023 | Hing C Wong | CEO | Buy | 20 | $64.80 | $1,296.00 | 382,806 | |
| 5/30/2023 | Gary M Winer | Director | Buy | 21 | $60.80 | $1,276.80 | 346 | |
| 5/30/2023 | Hing C Wong | CEO | Buy | 75 | $62.00 | $4,650.00 | 382,736 | |
| 5/26/2023 | Rebecca Byam | CFO | Buy | 500 | $66.40 | $33,200.00 | 11,504 | |
| 5/24/2023 | Rebecca Byam | CFO | Buy | 500 | $64.40 | $32,200.00 | 10,504 | |
| 5/22/2023 | Rebecca Byam | CFO | Buy | 836 | $61.20 | $51,163.20 | 9,878 | |
HCW Biologics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/6/2025 | Golden State Wealth Management LLC | 10,000 | $40K | 0.0% | N/A | 0.694% |  |
| 5/2/2024 | Pullen Investment Management LLC | 85,116 | $0.15M | 0.1% | N/A | 0.225% | |
| 2/9/2024 | Avantax Planning Partners Inc. | 179,541 | $0.22M | 0.0% | N/A | 0.499% | |
| 2/9/2023 | HighTower Advisors LLC | 269,869 | $0.52M | 0.0% | +19.6% | 0.752% | |
| 11/15/2021 | HighTower Advisors LLC | 14,000 | $45K | 0.0% | N/A | 0.039% | |
Data available starting January 2016
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Read More on HCW Biologics
Volume
24,047 shs
Average Volume
139,791 shs
Market Capitalization
$5.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.66
Who are the company insiders with the largest holdings of HCW Biologics?
